Phil's last sentence below could handle any oversubscription.
Chief Executive Officer, Mr Phillip Lynch said, “This additional result further underscores
the potential patient utility and commercial applicability for Zantrene. We will be allocating
additional resources to ensure this discovery can be comprehensively addressed.”
Phil's last sentence below could handle any...
-
- There are more pages in this discussion • 150 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
-0.040(2.37%) |
Mkt cap ! $281.2M | |||
| Open | High | Low | Value | Volume |
| $1.69 | $1.69 | $1.64 | $50.53K | 30.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 539 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 731 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |